Regular Article CLINICAL TRIALS AND OBSERVATIONS A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
نویسندگان
چکیده
Fred Hutchinson Cancer Research Center, Seattle, WA; Southwest Oncology Group Statistical Center, Seattle, WA; City of Hope Medical Center, Duarte, CA; University of New Mexico, Albuquerque, NM; Vancouver General Hospital, Vancouver, BC, Canada; University of Toronto, Toronto, Ontario, Canada; University of Chicago, Chicago, IL; University of Michigan, Ann Arbor, MI; Loyola University Medical Center, Maywood, IL; Medical University of South Carolina, Charleston, SC; Memorial Sloan-Kettering Cancer Center, New York, NY; and Karolinska University Hospital, Stockholm, Sweden
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 acute myeloid leukemia
This open-label, dose-escalation study evaluated the safety and efficacy of singleagent gemtuzumab ozogamicin, a humanized anti-CD33 antibody–targeted chemotherapeutic agent, for pediatric patients with multiple relapsed or primary refractory acute myeloid leukemia (AML). Twenty-nine children 1 to 16 years of age (relapsed disease, 19; refractory disease, 10) received gemtuzumab ozogamicin rang...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
The feasibility of combining gemtuzumab ozogamicin (GO) with intensive chemotherapy as first-line treatment of acute myeloid leukemia (AML) was assessed in 72 patients, aged 17 to 59 years, as a prelude to the United Kingdom Medical Research Council (MRC) AML15 trial. Sixty-four patients received induction chemotherapy (DAT [daunorubicin, ara-C, thioguanine], DA [daunorubicin, ara-C], or FLAG-I...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
The median age at the time of diagnosis of acute myeloid leukemia (AML) in the United States is 68 years. With increasing age, the response rates to standard chemotherapy decrease and early mortality increases. Data from 5 SWOG trials show that the complete response (CR) rates to chemotherapy-based treatment regimens fall from 65% for patients,56 years of age to 46%, 39%, and 33% with each addi...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
The primary objective of this phase 3 study was to determine whether postconsolidation immunotherapy with interleukin-2 (IL-2) and histamine dihydrochloride (HDC) improved the leukemia-free survival (LFS) of adult patients with acute myeloid leukemia (AML) in complete remission (CR). Three hundred twenty patients with AML (median age, 57 years; range, 18-84 years) were stratified by CR1 or subs...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
To assess the prognostic relevance of mutations in the NPM1 gene encoding a nucleocytoplasmic shuttle protein in younger adults with acute myeloid leukemia (AML) and normal cytogenetics, sequencing of NPM1 exon 12 was performed in diagnostic samples from 300 patients entered into 2 consecutive multicenter trials of the AML Study Group (AMLSG). Treatment included intensive double-induction thera...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013